- Oral presentation
- Open Access
Clinical Trials of DNA and Recombinant Adenovector (rAd) Vaccines for HIV
© The Author(s) 2005
Published: 8 December 2005
Gene-based vaccine delivery is an important strategy for induction of T cell responses that may be critical for a successful AIDS vaccine. Despite promising results in animal models, evidence of immune responses to DNA and rAd vaccines in humans has been limited.
Materials and methods
Three Phase I studies have evaluated a series of DNA and rAd vaccine candidates expressing constructs encoding clades A, B, and C Envelope and clade B Gag and Pol with or without Nef, as fusion proteins or individually.
T cell and antibody responses are detected by IFN-α ELISpot and FACS detection of intracellular IL-2 or IFN-α in the large majority of vaccinees. Env peptide pools elicit the strongest response, but the 6-plasmid and rAd product also induced robust responses to Gag, Pol, and Nef. Both T cell and humoral responses were dose dependent. The T cell responses induced by DNA are detectable for at least 52 weeks, and the pattern of cytokine expression evolves over time with fewer IFN-γ and more IL-2 producing T cells at one year.
DNA and rAd5 vaccine candidates are well tolerated and induce broad, durable immune responses. The combination will be tested in Phase II trials beginning 4Q2005.